Log in to save to my catalogue

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4151214

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial

Publication information

Publisher

United States: American Society for Clinical Investigation

More information

Scope and Contents

Contents

The phase III RV144 HIV-1 vaccine trial estimated vaccine efficacy (VE) to be 31.2%. This trial demonstrated that the presence of HIV-1-specific IgG-binding Abs to envelope (Env) V1V2 inversely correlated with infection risk, while the presence of Env-specific plasma IgA Abs directly correlated with risk of HIV-1 infection. Moreover, Ab-dependent c...

Alternative Titles

Full title

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4151214

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4151214

Other Identifiers

ISSN

0021-9738

E-ISSN

1558-8238

DOI

10.1172/JCI75539

How to access this item